Cost-effectiveness of maintenance therapy after first-line treatment in metastatic colorectal cancer

被引：1
|
作者：
Giuliani, Jacopo [1 ]
Mantoan, Beatrice [2 ]
Bonetti, Andrea [1 ]
机构：
[1] Az ULSS 9 Scaligera, Dept Oncol, Legnago, VR, Italy
[2] Az ULSS 9 Scaligera, Dept Diagnost Imaging, Legnago, VR, Italy
来源：
JOURNAL OF ONCOLOGY PHARMACY PRACTICE | 2022年 / 28卷 / 01期
关键词：
PHASE-III TRIAL; PLUS BEVACIZUMAB; NON-INFERIORITY; OPEN-LABEL; CHEMOTHERAPY; ONCOLOGY; CAPECITABINE; BIOSIMILARS; INDUCTION; ERLOTINIB;
D O I：
10.1177/10781552211038929
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：194 / 198
页数：5
相关论文
共 50 条
  • [1] Cost-effectiveness of capecitabine and bevacizumab maintenance treatment after first-line induction treatment in metastatic colorectal cancer
    Franken, M. D.
    van Rooijen, E. M.
    May, A. M.
    Koffijberg, H.
    van Tinteren, H.
    Mol, L.
    ten Tije, A. J.
    Creemers, G. J.
    van der Velden, A. M. T.
    Tanis, B. C.
    Groot, C. A. Uyl-de
    Punt, C. J. A.
    Koopman, M.
    van Oijen, M. G. H.
    [J]. EUROPEAN JOURNAL OF CANCER, 2017, 75 : 204 - 212
  • [2] COST-EFFECTIVENESS OF CETUXIMAB AS FIRST-LINE TREATMENT FOR METASTATIC COLORECTAL CANCER IN THE UNITED STATES
    Ortendahl, J. D.
    Bentley, T. G.
    Anene, A. M.
    Purdum, A. G.
    Bolinder, B.
    [J]. VALUE IN HEALTH, 2014, 17 (03) : A86 - A86
  • [3] The cost-effectiveness of bevacizumab in the first-line treatment of metastatic colorectal cancer in England and Wales
    Tappenden, P.
    Jones, R.
    Paisley, S.
    Carroll, C.
    [J]. EUROPEAN JOURNAL OF CANCER, 2007, 43 (17) : 2487 - 2494
  • [4] Cost-Effectiveness of Cetuximab as First-line Treatment for Metastatic Colorectal Cancer in the United States
    Shankaran, Veena
    Ortendahl, Jesse D.
    Purdum, Anna G.
    Bolinder, Bjorn
    Anene, Ayanna M.
    Sun, Gordon H.
    Bentley, Tanya G. K.
    [J]. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2018, 41 (01): : 65 - 72
  • [5] Cost-Effectiveness of First-Line Cetuximab in Metastatic Colorectal Cancer in Saudi Arabia
    Elsamany, Shereef
    Elsisi, Gihan Hamdy
    Hassanin, Fayza Ahmed Mohamed
    Saleh, Khaldoon
    Tashkandi, Emad
    [J]. VALUE IN HEALTH REGIONAL ISSUES, 2022, 28 : 67 - 75
  • [6] Cost-effectiveness of FOLFIRINOX for first-line treatment of metastatic pancreatic cancer
    Attard, C. L.
    Brown, S.
    Alloul, K.
    Moore, M. J.
    [J]. CURRENT ONCOLOGY, 2014, 21 (01) : E41 - E51
  • [7] Cost-effectiveness of biomarker-directed bevacizumab for first-line therapy of persons with metastatic colorectal cancer
    Berry, Kristin
    Bensink, Mark Eliot
    Musa, Zahra
    Shankaran, Veena
    Lin, Edward H.
    Ladabaum, Uri
    Bodnar, Carolyn
    Birt, Michael
    Ramsey, Scott David
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [8] Cost-Effectiveness Analysis of Monoclonal Antibodies Associated With Chemotherapy in First-Line Treatment of Metastatic Colorectal Cancer
    Barufaldi, Laura A.
    de Albuquerque, Rita de C. R.
    do Nascimento, Aline
    Martins, Luis Felipe L.
    Zimmermann, Ivan R.
    de Souza, Mirian C.
    [J]. VALUE IN HEALTH REGIONAL ISSUES, 2023, 37 : 33 - 40
  • [9] Cost-effectiveness analysis of the addition of bevacizumab to first-line chemotherapy in metastatic colorectal cancer
    Villa, D.
    Hedden, L.
    Peacock, S.
    Kennecke, H. F.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [10] Cost-effectiveness of FOLFIRINOX for first-line treatment of metastatic pancreatic cancer.
    Attard, Cheryl L.
    Brown, Stephen
    Alloul, Karine
    Moore, Malcolm J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (04)
12345